WO2004035581A1 - スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 - Google Patents
スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 Download PDFInfo
- Publication number
- WO2004035581A1 WO2004035581A1 PCT/JP2002/010828 JP0210828W WO2004035581A1 WO 2004035581 A1 WO2004035581 A1 WO 2004035581A1 JP 0210828 W JP0210828 W JP 0210828W WO 2004035581 A1 WO2004035581 A1 WO 2004035581A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- dioxo
- triazaspiro
- alkyl group
- propano
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/20—Spiro-condensed systems
Definitions
- Memory T cells home via the lymph vessels and blood vessels to the lymph nodes again.
- B cells, intestinal intraepithelial T cells, ⁇ cells, ⁇ cells, and dendritic cells migrate and differentiate from bone marrow without passing through the thymus, and are involved in the immune response.
- MCP-1 and its receptor, CCR2 are involved in macrophage infiltration into sites of inflammation.
- Anti-MCP-1 antibody showed an inhibitory effect on monocyte and macrophage infiltration into glomeruli in a rat anti-Thy1.1 antibody nephritis model [Kidney Int, 1, 770 (1997)].
- AIDS Acquired immunodeficiency syndrome
- HIV human immunodeficiency virus
- CD4-positive cells Once the primary target cell, CD4-positive cells, is infected with HIV, HIV repeats proliferating in the patient's body and eventually catastrophically destroys the T cells responsible for immune function. During this process, the immune function gradually decreases, and various immunodeficiency states such as fever, diarrhea, and swelling of the lymph nodes are exhibited, and various opportunistic infections such as Kali pneumonia are easily caused. It is well known that such a condition is the onset of AIDS and induces malignant tumors such as cystic sarcoma and becomes serious.
- Fusin a cell membrane protein called Fusin was identified as a factor involved in HIV infection other than the four CD molecules [Science, 222, 872 (19%)]. This Fusin molecule was proved to be a receptor (ie, CXCR4) for stromal cell-derived factor-1 (Stromal Derived Factor-1: SDF_l). Furthermore, it has been demonstrated that SDF-1 specifically suppresses T cell tropism (X4) HIV infection in vitro [Nature, 382, 829 (1996), ature, 382, 833 (1996)]. That is, it is considered that the binding of SDF_1 to CXCR4 prior to HIV deprived HIV of a foothold for infecting cells, thereby inhibiting HIV infection.
- CXCR4 stromal cell-derived factor-1
- CCR 5 a receptor for RANTE S, MIP-1 and MIP-1] 3
- R5 macrophage-tropic
- CXCR4 or CCR5 a receptor for RANTE S, MIP-1 and MIP-1
- CXCR4 or CCR5 could be HIV infection inhibitors. It is.
- low-molecular-weight compounds initially discovered as inhibitors of HIV infection have been shown to be actually antagonists of CXCR4 [Nature Medicine, 4, 72 (1998)].
- Z and q Z are each independently a number from 2 to 6,
- mZ is a number from 0 to pZ
- nZ is a number from 0 to qZ
- One (L z ) is a bond or is selected from carbon, nitrogen, sulfur and oxygen Is a divalent substituted or unsubstituted chain consisting of 1 to 10 atoms, Q z is a basic group containing one or more basic radicals, and R 3 Z is one Or it is an acidic group containing two or more acidic radicals. There is a description that the compound represented by) is useful for inhibiting platelet aggregation.
- mY or 1 Y each independently represents 0, 1, 2, 3, 4 or 5;
- R 1 Y represents a hydrogen atom, a C1-8 alkyl group, a C2-8 alkyl group, a C2-8 benzoquinone group,
- W Y represents a single bond, a C 1-3 alkyl group, a C 1-3 alkyl group substituted with oxo, etc.
- Q Y is one NR 2 - one O-, one S-, one S (O) one or one S 0 2 - represents, is chi gamma, a single bond, C. 1 to 3 alkyl groups, substituted with Okiso etc. Represents a C 1-3 alkyl group, etc.
- ⁇ ⁇ — ⁇ The ⁇ ring represents phenyl, naphthyl, or heteroaryl. However, the definition of each symbol is partly excerpted. ) Is useful as a chemokine receptor modulator. Disclosure of the invention
- the present inventors have conducted intensive studies to find compounds that control the actions of various chemokines and chemokine receptors. As a result, the spiro complex ring derivative represented by the general formula (I) has been developed. Have been achieved, and the present invention has been completed.
- the present invention
- R 195 represents a hydrogen atom, a C1-8 alkyl group, a phenyl group, or a C1-8 alkyl group substituted by a phenyl group;
- R 10 s R 22 , R 24 and R 26 are each independently:
- R 37 and R 39 are each independently a hydrogen atom, a Cl-8 alkyl Represents a C 1-8 alkyl group substituted by a group, Cy cl, or Cy c 1,
- R 35 and R 36 are joined together to form (1) C2-6 anoalkylene group, (2) — (C2-6 anoalkylene group) 10— (C2-6 alkylene group) 1, (3) — ( A C 2-6 alkylene group) one S— (C 2-6 alkylene group) one, or (4) one (C 2-6 alkylene group) one NR 196 — (C 2-6 alkylene group) one,
- R 196 represents a hydrogen atom, a C 1-8 alkyl group, a fuel group, or a C 1-8 alkyl group substituted by a fuel group;
- R 38 and R 40 each independently represent a C 1-8 alkyl group, Cy cl, or a C 1-8 alkyl group substituted by Cy c 1;
- Cy cl is a C 3-15 monocyclic carbocycle, or a bicyclic, tricyclic fused or spiro carbocycle, or 1-4 nitrogen atoms, 1-3 oxygen atoms and / or 1 Represents a 3- to 5-membered monocyclic heterocyclic ring containing up to 3 sulfur atoms, or a bicyclic, tricyclic fused or spiro heterocyclic ring,
- Cy c 1 may be substituted by 1-5 R 51 ,
- R 55 2- COOR 56, ( g) - CONR 57 R 58, (h) _N R 59 COR 60, (i) - S0 2 NR 61 R 62, (j) - OCOR 63, (k) - NR 64 S0 2 R 65 , 1- NR 66 C OOR 67 , (m) — NR 68 CONR 69 R 70 , (n) -B (OR 71 ) 2 , (0) _SO 2 R 72 , (p) -N (SO 2 R 72 ) a C 1-8 alkyl group, a C 2-8 alkenyl group, or a C 2-8 alkyl group, which is substituted by 1 to 5 groups arbitrarily selected from 2 and (q) keto groups.
- R 52 to R 62 , R 64 , R 66 and R 68 to R 71 are each independently: (1) a hydrogen atom, (2) a C 1-8 alkyl group, (3) a C 2-8 alkenyl group, (4) C2-8 Arukini Le group, (5) Cy c 2 or (6) Cy c 2, one oR 73, C 1 ⁇ 8 alkyl groups substituted by one COOR 74 or a NR 75 R 76,, Represents a C 2-8 alkenyl group, or a C 2-8 alkynyl group, R 57 and R 58 , R 61 and R 62 , R 69 and R 70 are joined together to form (1) a C 2-6 alkylene group, (2) — (C 2-6 alkylene group) one O— (C 2 ⁇ 6 alkylene groups)
- R 197 represents a hydrogen atom, a C1-8 alkyl group, a phenyl group, or a C1-8 alkyl group substituted by a phenyl group;
- R 63 , R 65 s R 67 and R 72 each independently represent (1) a C 1-8 alkyl group, (2) a C 2-8 alkenyl group, (3) a C 2-8 alkynyl group, 4) C yc 2 or (5) Cy c 2, one oR 73, C l ⁇ 8 alkyl groups substituted by one COOR 74 or a NR 75 R 76,,, C2 ⁇ 8 alkenyl - group or C2 ⁇ , 8 represents an alkynyl group,
- R 73 to R 76 each independently represent a hydrogen atom, a C 1-8 alkyl group, Cy c 2 or a C 1-8 alkyl group substituted by Cy c 2;
- Cy c 2 represent the same meaning as Cy c 1, C yc 2 may be substituted Te 1-5 amino R 77 Niyotsu,
- R 78 ⁇ R 84, R 161_ R 164 ⁇ R 166, R 168 and R i 70 ⁇ R i 72 are each, independently, (a) hydrogen atom, (b) C 1 ⁇ 8 alkyl group, (c) C 2-8 alkenyl group, (d) C 2 ⁇ 8 Anorekiniru group, (e) Cy c 6, (f) C yc 6, one oR 174, -COO R 175, one NR 176 R 177 or a CONR 178 R, A C 1-8 alkyl group, a C 2-8 alkenyl group, or a C 2-8 alkynyl group substituted by 179 . Show
- R 174 to R 177 are each independently a (1) hydrogen atom, ( 2 ) C 1-8 alkyl group, (3) Cy c 6 or (4) C 1-8 alkyl substituted by Cy c 6 Represents a group,
- R i 78 and R i 79 are joined together: c 2-6 alkylene group, (2) — (C 2-6 alkylene alkylene group) O— (C 2-6 alkylene group) 1, (3) — (C 2-6 alkylene group) one S_ (C 2-6 alkylene group) one, or (4) one (C 2-6 alkylene group) one NR 199 — (C 2-6 alkylene group) one,
- R 199 represents a hydrogen atom, a C1-8 alkyl group, a phenyl group, or a C1-8 alkyl group substituted by a phenyl group;
- Cy c 6 is a C3-8 monocyclic carbocyclic or 3-8 membered monocyclic ring containing 1-4 nitrogen atoms, 1-2 oxygen atoms and Z or 1-2 sulfur atoms Represents a heterocycle of the formula, wherein Cy 6 is optionally substituted by 1-5 R 180 , wherein R 180 is (1) C1-8 alkyl group,
- R 2 ° 2 represents a hydrogen atom, a C 1-8 alkyl group, a fuel group, or a C 1-8 alkyl group substituted by a fuel group,
- Cy c 4 has the same meaning as Cy c 1; Cy c 4 may be substituted by 1 to 5 R 144 ; R 1 4 4 has the same meaning as R 5 1 ;
- n 0 to 5
- the C1-8 alkyl group means a methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl group and isomers thereof.
- a C1-18 alkyl group is a methyl, ethyl, propyl, butyl, pentyl, hexinole, heptinole, otatyl, noel, desinole, pendecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl group and It means those isomers.
- the C 2-18 alkyl group means a C 2-18 alkylene group which may have 1 to 9, preferably 1 to 4, triple bonds.
- 3- to 15-membered monocyclic heterocyclic ring containing 1 to 4 nitrogen atoms, 1 to 3 oxygen atoms and Z or 1 to 3 sulfur atoms, or bicyclic or tricyclic fused or spiro heterocyclic
- the ring is, for example, a 3- to 15-membered monocyclic heterocyclic ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms and / or 1-3 sulfur atoms, or a bicyclic or tricyclic Or a spiro heterocyclic aryl, or a part or all thereof is saturated.
- 3- to 15-membered monocyclic heterocyclic ring containing 1 to 4 nitrogen atoms, 1 to 3 oxygen atoms and / or 1 to 3 sulfur atoms, or bicyclic or tricyclic fused or Pyroheterocyclic aryls include pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepin, thiophene, thiamine (chopyran), chepin, isoxazole, oxazole, oxazole, Thiazolone, isothiazole, brazan, oxaziazole, oxazine, oxazine, oxazepine, oxazineazepine, thiadiazole, thiazine, thiazineazine,
- a 3- to 8-membered monocyclic heterocycle containing 1 to 4 nitrogen atoms, 1 to 2 oxygen atoms and Z or 1 to 2 sulfur atoms is, for example, 1 to 4 nitrogen atoms
- a 3- to 8-membered monocyclic heterocyclic aryl containing 1 to 2 oxygen atoms and 1 to 2 sulfur atoms or 1 to 2 sulfur atoms, or a part or all of them are saturated.
- Examples of the 3- to 8-membered monocyclic heterocyclic aryl containing 1 to 4 nitrogen atoms, 1 to 2 oxygen atoms, and / or 1 to 2 sulfur atoms include pyrrole, imidazo mono, triazono, tetrazo 1.
- pyrazonole pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepin, thiophene, thiane (thiopyran), chepin, oxazole, isoxazonole, thiazole, isothiazole, isothiazole, thiazol Examples include xazine, oxazine diazine, oxazepine, oxazezepine, thiadiazole, thiazine, thiadiazine, thiazepine, and thiadiazepine ring.
- the R 2a group has the same meaning as the R 2 group except for the keto group and the thioketo group, and the other symbols have the same meanings as described above.
- Examples of the 4- to 7-membered saturated or partially saturated heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur represented by ring B include pyrroline, pyrrolidine, Imidazoline, imidazolidine, birazoli , Pyrazolidine, triazoline, triazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrohydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, peroxide mouth pyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, Dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetra
- each of the groups represented by R 1 , R 2 and R 3 is preferred.
- R 1 group a Cl to 18 alkyl group, a C 2 to 18 alkenyl group, a C 2 to 18 alkynyl group, a C 1 to 18 alkyl group substituted by Cyc 1 and a substituent by Cyc 1 A substituted C 2-18 alkyl group or a C 2-18 alkynyl group substituted by Cyc1, more preferably a Cl-18 alkyl group or substituted by Cyc1.
- C 1-6 alkyl group is there.
- Cy 1 is preferably a benzene ring, a pyrazole ring, an imidazonole ring, a furan ring, a thiophene ring, a benzodioxane ring, a thiazole ring, or a quinoline ring.
- R 77 as a substituent of Cy c 2 includes one of COOR 81 , one of CONR 83 R 84 , —NR 161 COR 162 , one of S 0 2 NR 163 R 164 , one of NR 166 SO 2 R 167 , or substituted by these Preferred are C 1-8 alkyl groups.
- R 167 is preferably a C 1-8 alkyl group, a C 1-8 alkyl group substituted with Cyc6, NR 176 R 177 , and more preferably methyl, ethyl, propyl, phenyl or the like. Phenyl, dimethylaminoethyl and the like.
- R 1 is a phenyl / reethyl group, a phenolic pill group, a phenylbutyl group, a phenylpentyl group, a phenylhexyl group, a 4-methoxyphenylmethyl group, a 4-propyloxyphenylmethyl group, —Phenyloxyphenylmethyl group, 3,5-dimethyl-11-phenylpyrazole-4-erynomethinole group, 2-pheninoleimidazonole-1,4-inolemethinole group, 5-ethylinolefuran-2-ylmethyl group, 5-Ethylthiophene-2-ylmethyl group, 3-chloro-1-5-methyl-1-phenylvirazol-4-ylmethyl group, 1,4-benzodioxane-16-ylmethyl group, 4- (4-methylsulfonylaminophenyloxy) Phenylmethyl group, 4- (4- (2-d
- non-toxic salts are included.
- common salts, acid addition salts, hydrate salts and the like can be mentioned.
- the compound of the present invention represented by the general formula (I) can be converted to a corresponding salt by a known method.
- Non-toxic, water-soluble salts are preferred.
- Suitable salts include salts of alkali metals (such as potassium and sodium), salts of alkaline earth metals (such as calcium and magnesium), ammonium salts, and pharmaceutically acceptable organic amines (tetramethylammonium, etc.).
- the compound of the present invention represented by the general formula (I) can be converted to a corresponding acid addition salt by a known method.
- the acid addition salts are preferably non-toxic and water-soluble.
- Suitable acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, or acetate, trifluoroacetate, lactate, tartrate, oxalate Such as, fumarate, maleate, citrate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, dalconate Organic salts.
- the compounds of the general formula (I) or their non-toxic salts are all preferred. Specific examples include the compounds described in the examples or non-toxic salts thereof. Quaternary The Anmoyuumu salt of the compound represented by the general formula (I), the nitrogen atom of the compound represented by formula (I), represents those quaternized I inhibit by R Q group.
- the R0 group represents a C1-8 alkyl group or a C1-8 alkyl group substituted by a phenyl group.
- the N-oxide of the compound represented by the general formula (I) means that the nitrogen atom of the compound represented by the general formula (I) is oxidized.
- the compound of the present invention represented by the general formula (I) can be produced by the following methods or the methods described in Examples.
- R 1 represents a group other than hydrogen
- This cyclization reaction is known.
- an acid acetic acid, trifluoroacetic acid, hydrochloric acid, p-toluenesulfonic acid, etc.
- a base triethylamine, diisopropylamine
- an organic solvent toluene, dichloromethane, dichloroethane, etc.
- the reaction is carried out at 110 to 120 ° C in the presence or absence of thiamine or lithium diisopropylamide.
- an operation for converting into the desired non-toxic salt may be performed by a known method.
- the compound represented by the general formula (Ia) is obtained by removing a compound in which R la is a protecting group for an amino group in the compound represented by the above general formula (Ia). It can be produced by subjecting it to a protection reaction.
- Examples of the protecting group for an amino group include a benzyl group, a benzyloxycarbonyl group, an aryloxycarbonyl group, a t-butoxycarbonyl group, and a trifluoroacetyl group.
- the protecting group for the amino group is not particularly limited as long as it is a group which can be easily and selectively eliminated, in addition to the above.
- T. W. Greene et al. Protective Groups in Organic Synthesis, Tnird Edition, Wilev-Interscience, New III, 1999 [this ci is used.
- the deprotection reaction by alkali hydrolysis is carried out, for example, in an organic solvent (methanol, tetrahydrofuran, dioxane, etc.) in a hydroxide of alkali metal (sodium hydroxide, Lithium hydroxide, lithium hydroxide, etc.), hydroxides of alkaline earth metals (barium hydroxide, calcium hydroxide, etc.) or carbonates (sodium carbonate, potassium carbonate, etc.) or their aqueous solutions or mixtures thereof And at a temperature of 0 to 40 ° C.
- an organic solvent methanol, tetrahydrofuran, dioxane, etc.
- a hydroxide of alkali metal sodium hydroxide, Lithium hydroxide, lithium hydroxide, etc.
- hydroxides of alkaline earth metals barium hydroxide, calcium hydroxide, etc.
- carbonates sodium carbonate, potassium carbonate, etc.
- the deprotection reaction under acid conditions is carried out, for example, in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate, anisol, etc.) in an organic acid (
- the reaction is carried out in acetic acid, trifluoroacetic acid, methanesulfonic acid or the like, or an inorganic acid (hydrochloric acid, sulfuric acid or the like) or a mixture thereof (hydrogen bromide / acetic acid or the like) at a temperature of 0 to 100 ° C.
- the deprotection reaction by hydrogenolysis (for example, benzyl group, benzyloxycarbonyl group, aryloxycarbonyl group) is carried out, for example, in a solvent (ether-based (tetrahydrofuran, dioxane, dimethyloxetane, getyl ether, etc.)).
- a solvent ether-based (tetrahydrofuran, dioxane, dimethyloxetane, getyl ether, etc.)
- Alcohols methanol, ethanol, etc.
- benzenes benzene, toluene, etc.
- ketones acetone, methyl ethyl ketone, etc.
- nitriles acetutrile, etc.
- amides dimethylformamide, etc.
- Water ethyl acetate, acetic acid or a mixed solvent of two or more of them) in the presence of a catalyst (palladium-one carbon, palladium black, palladium hydroxide-one carbon, platinum oxide, Raney nickel, etc.) at normal pressure or Perform at a temperature of 0 to 200 ° C in a hydrogen atmosphere under pressure or in the presence of ammonium formate. It is.
- a catalyst palladium-one carbon, palladium black, palladium hydroxide-one carbon, platinum oxide, Raney nickel, etc.
- the deprotection reaction using a metal complex is performed, for example, in an organic solvent (dichloromethane, dimethylformamide, tetrahydrofuran, etc.), a trapping reagent (hydrogenated triptyltin, dimedone, etc.) and Z or an organic acid (acetic acid, etc.).
- the reaction is performed at a temperature of 0 to 40 ° C. using a metal complex (such as a tetrakistriphenylphosphine palladium (0) complex) in the presence of
- the compound of the present invention represented by the general formula (I) can also be produced by the methods shown in the following (c) to (j).
- R 1 is a C 1-18 alkyl group, a C 2-18 alkenyl group, a C 2-18 alkynyl group or a C l- substituted with various substituents.
- R 1 C is a C 1-17 alkyl group, a C 2-17 alkenyl group, a C 2-17 alkyl group, or (a) a halogen atom, (b) —CONR 7 R 8 , (c) one COO R (d) - OR 14 , (e) -SR 15, over NR 16 R 17, (g) - NR 18 COR 19, (h) - SO 2 NR 20 R 21, (i) - OCOR 22, 1-NR 23 S0 2 R 24, (k) one NR 25 COOR 26, (1) - NR 27 CONR 28 R 29, (m) C ycl, (n) keto group, and (o) -N (S0 2 R 24) is substituted by a group selected from 2 optionally represents a C l to 1 7 alkyl group, C 2 to L 7 alkenyl or C. 2 to 1 7 alkyl group, the other symbols Represents the same meaning as described above.)
- the compound can be produced by subjecting the compound to a reduction amination reaction.
- This reductive amination reaction is known.
- a reducing agent for example, sodium triacetoxyborohydride, cyano aqueous solution
- an organic solvent for example, dichloroethane, dichloromethane, dimethylformamide, acetic acid or a mixture thereof
- Sodium borohydride at a temperature of 0 to 40 ° C.
- the reductive amination reaction can also be performed on a compound in which the nitrogen atom in R 1 represents N-oxide.
- R 1 is a C 1-18 alkyl group, a C 2-18 alkenyl group, a C 2-18 alkyl group or a C ⁇ substituted with various substituents. Represents an alkyl group, a C2-18 alkyl group, or a C2-18 alkyl group, and R 1 is a nitrogen atom and one CH (R ld )-(where R ld is C 1 Represents a C 17 alkyl group, a C 2-17 alkyl group or a C 2-17 alkyl group), ie, a compound represented by the general formula (Id)
- R ld represents a Cl-17 alkyl group, a C2-17 alkenyl group, a C2-17 alkyl group, and other symbols have the same meanings as described above.
- a Lewis acid for example, Lewis acid (triethylamine, diisopropylethylamine, etc.) in an organic solvent (eg, dichloroethane, dichloromethane, etc.) is used in the presence of a tertiary amine (triethylamine, diisopropylethylamine, etc.).
- a tertiary amine triethylamine, diisopropylethylamine, etc.
- titanium tetrachloride, etc. at 0-40 ° C, and at a temperature of 0-40 ° C in the presence of a reducing agent (sodium triacetoxyborohydride, sodium cyanoborohydride, etc.).
- a reducing agent sodium triacetoxyborohydride, sodium cyanoborohydride, etc.
- the compound can be produced by subjecting the compound to an amidation reaction.
- This amidation reaction is known, and is carried out in an organic solvent (eg, chloroform, dichloromethane, getyl ether, tetrahydrofuran, dioxane, dimethinolehonolemamide) in a tertiary amine (isopropylethylamine, pyridine, triethylamine). Dimethylaniline, dimethylaminopyridine, etc.) or an aqueous alkali solution (such as aqueous sodium bicarbonate solution or sodium hydroxide solution) at 0 to 40 ° C.
- an organic solvent eg, chloroform, dichloromethane, getyl ether, tetrahydrofuran, dioxane, dimethinolehonolemamide
- a tertiary amine isopropylethylamine, pyridine, triethylamine.
- Dimethylaniline, dimethylaminopyridine, etc. or an aqueous
- the compound can be produced by subjecting the compound to a sulfonamidation reaction.
- This sulfonamidation reaction is known, and is carried out in a tertiary amine (diisopropylethylamine, pyridine, triethylamine, dimethinorea) in an organic solvent (e.g. 0 to 40 in the presence of phosphorus, dimethylaminopyridine and the like. It is carried out by reacting with C.
- a tertiary amine diisopropylethylamine, pyridine, triethylamine, dimethinorea
- organic solvent e.g. 0 to 40 in the presence of phosphorus, dimethylaminopyridine and the like. It is carried out by reacting with C.
- the reaction between the general formula (Ib) and the general formula (VH-2) is known, and is performed in an organic solvent (eg, chlorophonolem, dichloromethane, dichloroethane, dimethinolehonolemamide, diethyl ether, tetrahydrofuran).
- an organic solvent eg, chlorophonolem, dichloromethane, dichloroethane, dimethinolehonolemamide, diethyl ether, tetrahydrofuran.
- the reaction is carried out at ° C.
- R 1 is —CH 2 —CH (OH) -R lh
- R lh is a C 1-16 alkyl group, a C 2-16 alkyl group, a C 2-16 Alkynyl group or a C1-16 alkyl group, a C2-16 alkenyl group or a C2-16 alkynyl group substituted by various substituents
- This reaction is known, and is carried out in the presence or absence of a tertiary amine (triethylamine, N-methylmorpholine, etc.) in an organic solvent (methanol, ethanol, 2-propanol, tetrahydrofuran, acetoethryl, etc.).
- a tertiary amine triethylamine, N-methylmorpholine, etc.
- an organic solvent methanol, ethanol, 2-propanol, tetrahydrofuran, acetoethryl, etc.
- Compounds having at least one carboxyl, hydroxyl, amino or thiol group in the compounds represented by the general formula (I) include carboxyl groups each protected by a suitable protecting group, The reaction can be performed by using the compound having a group containing a hydroxyl group, an amino group or a thiol group to carry out the above-mentioned reactions (a) to), followed by deprotection of a protective group.
- Examples of the carboxyl-protecting group include a methyl group, an ethyl group, a t-butyl group, a benzyl group, and an aryl group.
- hydroxyl-protecting group examples include a methoxymethyl group, a 2-tetrahydropyranyl group, a t-butyldimethylsilyl group, a t-butyldiphenylsilyl group, an acetyl group, and a benzyl group.
- Examples of the protecting group for an amino group include a benzyloxycarbonyl group, an aryloxycarbol group, a t-butoxycarbonyl group, a trifluoroacetyl group, and a 9-fluoromethoxycarbonyl group.
- Examples of the thiol-protecting group include a benzyl group, a methoxybenzyl group, an acetamidomethyl group, a triethylmethynole group, and an acetyl group.
- the protecting group for the carboxyl group, hydroxyl group, amino group or thiol group is not particularly limited as long as it can be easily and selectively eliminated, in addition to the above. For example, those described in T. W. Greene et al., Protective Groups in Organic Svnthesis, Third Edition, Wiley-Interscience, New York, 1999 are used.
- deprotection reaction of the protecting group of the amino group is carried out by the method described above.
- Deprotection reactions of carboxyl, hydroxyl or thiol protecting groups are well known and include, for example, (1) alkaline hydrolysis,
- (1), (2), (3) and (5) are carried out in the same manner as in the above-mentioned deprotection reaction of the amino-protecting group.
- the deprotection reaction of the silyl group is carried out, for example, in an organic solvent (tetrahydrofuran, acetonitrile, etc.) using tetrabutylammonium fluoride at a temperature of 0 to 40 ° C. .
- the desired compound of the present invention can be easily produced by properly using these deprotection reactions.
- R represents a C 1-8 alkyl group or a C 1-8 alkyl group substituted by a phenyl group, and Q represents a halogen atom.
- This reaction is known and is carried out, for example, in an organic solvent (acetone, dimethylformamide, methylethylketone, etc.) at a temperature of 0 to 40 ° C.
- organic solvent acetone, dimethylformamide, methylethylketone, etc.
- the compound in which at least one nitrogen atom represents N-oxide can be produced by subjecting the compound represented by the general formula (I) produced above to an oxidation reaction.
- This oxidation reaction is known, for example, in an appropriate organic solvent (dichloromethane, chlorophonolem, benzene, hexane, t-butyl / leanoreconore, etc.)
- Oxidizing agents hydrogen peroxide, sodium periodate, sodium nitrite, sodium perborate, peracids (eg, 3-chloroperbenzoic acid, peracetic acid, etc.), oxone ("potassium peroxide”)
- the reaction is carried out at a temperature of 20 to 60 ° C. in the presence of “xoxomonosulfate” (hereinafter abbreviated as “oxone”), potassium permanganate, chromic acid, etc.).
- T is one L-one (polystyrene resin), a C1-8 alkyl group, a C3-8 monocyclic carbocycle, or a C3-8 monocyclic carbocycle or a 5- to 7-membered monocycle.
- Cyclic represents a C 1-8 alkyl group substituted by a heterocyclic ring, the other symbols represent the same meaning as described above, and L represents a divalent group.
- ⁇ -2 polystyrene resin
- examples of the divalent group represented by L include a methylene group.
- terminal amino group polystyrene resin that is, NH 2 — L— (Poly Examples of the (ethylene resin) include an aminomethyl polystyrene resin.
- the compound represented by the general formula ( ⁇ ) can be produced by commercially available power, a known method, or a method described in Examples described later.
- commercially available products include benzyl isocyanide, butyl isocyanide, and 2-morpholinoethyl isocyanide.
- Other starting materials and each reagent in the present invention are known per se or can be produced by a known method.
- the reaction product is washed multiple times with a usual purification means, for example, a solvent (dimethylformamide, dichloromethane, methanol, tetrahydrofuran, toluene, acetic acid / toluene, etc.).
- a solvent dimethylformamide, dichloromethane, methanol, tetrahydrofuran, toluene, acetic acid / toluene, etc.
- the product of the final reaction may be purified by conventional purification means, for example, distillation under normal or reduced pressure, high performance liquid chromatography using silica gel or magnesium silicate, thin-layer chromatography, or column chromatography or washing, reprocessing. It can be purified by a method such as crystallization.
- a technique to screen for compounds that inhibit the binding of HIV to CXCR4 or CCR5, a receptor on CD4-positive cells could be an Atsushi system that uses the HIV virus directly.
- the use of the HIV virus for mass screening is not practical because of its difficulties in handling.
- the macrophage tropism (R5) HIV-1 and RANTES, MIP-1 and MIP-1] 3 bind to CCR5 together, indicating that HIV and RANTES, MIP-1 ⁇ , It can be predicted that the CCR5 binding site on both the MI ⁇ _1 j3 side and the RANTE S, MIP-1 ⁇ , MIP-11jS and HIV binding sites on the CCR5 side have some common features. .
- the endogenous CCR5 is substituted for HIV instead of HIV.
- Atsey systems using RAN TES, MIP-1 and MIP-1 which are sex ligands are available.
- MIP-1 A system that measures the effect of Ca ions induced via CCR5 on transient elevations is feasible.
- T cell tropism (X4) A similar idea is possible because both HIV and SDF-1 bind to CXCR4.
- Human placenta cDNA was prepared using Marathon cDNA amplification kit (Clontech).
- CHO-dhfr (-) was cultured using Ham's F-12 (containing fetal serum (10%), penicillin (50 U / ml), and streptomycin (S OmgZml)). The transduced cells were cultured with blasticidin (5 mg Zml) as described above.
- CCR 5ZCHO cells The established human CCR 5 stably over-expressing CHO cells (CCR 5ZCHO cells) were suspended in Ham's F-12 medium, and FB S (1 0%), 9 6 well plate in 3.0 X 1 0 6 so that a cell well Involved. 3 After culturing at 7 ° C for 1 day, remove the culture supernatant and remove Ham's F-12 medium (Fura-2AM (5 ⁇ ), Probenecid (2.5 mM) and HE PES (2 OmM; ⁇ 7.4) was added to the wells, and incubated at 37 ° C for 1 hour in the light-shielded state.
- Fura-2AM 5 ⁇
- Probenecid 2.5 mM
- HE PES 2 OmM; ⁇ 7.4
- the compound of the present invention exhibited 50% or more inhibition at 10 // M.
- the compound of Example 1 (1) has IC 5 .
- the value was 0.74 ⁇ M
- the compound of Example 5 was 0.012 ⁇ M.
- the toxicity of the compound of the present invention is extremely low, and it can be determined that the compound is sufficiently safe for use as a medicament.
- the compound of the present invention represented by the general formula (I) controls the action of chemokine z-chemokine receptor, and thus can be used for various inflammatory diseases, asthma, atopic dermatitis, Measles, allergic disease (allergic one broncho-pulmonary aspergillosis, allergic eosinophilic gastroenteropathy, etc.), nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemia reperfusion Injury control, multiple sclerosis, ulcerative colitis, acute respiratory distress syndrome, shock associated with bacterial infection, diabetes, treatment of autoimmune disease, transplant rejection, immunosuppression, prevention of cancer metastasis, acquired immunodeficiency Useful for prevention and Z or treatment of the syndrome.
- allergic disease allergic one broncho-pulmonary aspergillosis, allergic eosinophilic gastroenteropathy, etc.
- the compound of the present invention represented by the general formula (I), a non-toxic salt thereof, an acid addition salt thereof, or a hydrate thereof for the above-mentioned purpose, the compound is usually administered systemically or locally, orally or non-orally. It is administered in oral form.
- Dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but usually, per adult, in the range of lmg to lOOmg, once orally several times a day Parenteral administration once or several times daily, in the range of lmg to 100 mg per adult per dose (preferably, Intravenous administration) or continuous intravenous administration for 1 hour to 24 hours per day.
- a dose smaller than the above-mentioned dose may be sufficient, or may be required beyond the range.
- Solid preparations for oral administration include tablets, pills, capsules, powders, granules and the like. Forceps include hard capsules and soft capsules.
- one or more of the active substance (s) is intact or excipients (ratatose, mannitol, glucose, microcrystalline cellulose, starch, etc.), binders (hydroxypropylcellulose, polyviel).
- excipients ratatose, mannitol, glucose, microcrystalline cellulose, starch, etc.
- binders hydroxypropylcellulose, polyviel.
- disintegrant calcium fiber glycolate, etc.
- lubricant magnesium stearate, etc.
- solubilizer solubilizer
- a coating agent sucrose, gelatin, hydroxypropinoresenolylose, hydroxypropinolemethinoresenolylose phthalate, etc.
- a coating agent such as sucrose, gelatin, hydroxypropinoresenolylose, hydroxypropinolemethinoresenolylose phthalate, etc.
- capsules of absorbable materials such as gelatin.
- Liquid preparations for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups, elixirs and the like.
- one or more active substances are dissolved, suspended or emulsified in a commonly used diluent (such as purified water, ethanol or a mixture thereof).
- this solution is a wetting agent, suspending agent, emulsifier, sweetener, flavor, fragrance, preservative, buffer Etc. may be contained.
- Injections for parenteral administration include solutions, suspensions, emulsions, and solid injections that are used by dissolving or suspending in a solvent for use. Injectables are used by dissolving, suspending or emulsifying one or more active substances in a solvent.
- the solvent for example, distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol and the like, and combinations thereof are used.
- this injection contains a stabilizer, a dissolution aid (glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifier, a soothing agent, a buffer, a preservative, and the like.
- a sterile solid preparation for example, a lyophilized product, can be manufactured and then used after dissolving in sterilized or sterile distilled water for injection or other solvents before use.
- compositions for parenteral administration include topical solutions, ointments, salves, inhalants, sprays, suppositories and vaginal preparations containing one or more active substances and prescribed in a conventional manner. Pessaries etc. are included.
- Sprays may contain, besides the commonly used diluents, buffers that provide isotonicity with stabilizers such as sodium bisulfite, for example, isotonic agents such as sodium chloride, sodium tenoate or citric acid. It may be contained.
- buffers that provide isotonicity with stabilizers such as sodium bisulfite, for example, isotonic agents such as sodium chloride, sodium tenoate or citric acid. It may be contained.
- Methods for producing spray agents are described in detail, for example, in U.S. Pat. Nos. 2,868,691 and 3,095,355.
- the solvent in kakkoko shown in the NMR section indicates the solvent used for the measurement.
- R * and S * do not represent absolute positions but only relative positions.
- Resin (1) Resin (2) Aminomethyl polystyrene resin 'hydrochloride (Resin (1); ⁇ indicates polystyrene resin.) (30.0 g) (1% dibutylbenzene copolymer, Watanabe Chemical, Watanabe No. A00062) was washed successively with dimethylformamide (300 ml), 10% diisopropylethylamine-dimethylformamide solution (300 ml) and dimethinolephonolemamide (300 ml). Dimethinole Honoremamide (2
- Resin (2) Resin (3) To a suspension of resin (2) obtained in Reference Example 1 in dichloromethane (300 ml) was added Liethylamine (18.8 ml), carbon tetrachloride (13.0 ml) and triphenylphosphine (35.4 g) were added, and the mixture was heated under reflux for 1 hour. After cooling the reaction solution at room temperature, the resin was collected by filtration. The resin was washed with dichloromethane (250 ml ⁇ 3 times), methanol (250 ml ⁇ 1 time) and dichloromethane (250 ml ⁇ 2 times), and dried under reduced pressure to obtain resin (3) (28.2 g). .
- N-aryloxycarbonyl 4-piridone (0.40 g), n-ptinoleamine (0.21 ml) and N- (t-butyl / (Reoxycarbonyl) -l-thioproline (0.51 g) was added, and the mixture was stirred at 65 ° C for 16 hours.
- the reaction solution was cooled at room temperature, and the resin was collected by filtration. The obtained resin was washed with tetrahydrofuran (5 ml ⁇ 2 times), methanol (5 ml ⁇ 2 times) and dichloromethane (5 ml ⁇ 2 times) to obtain a compound (1).
- the compound (4) produced in Reference Example 6 was suspended in a 1.25 M acetic acid-toluene solution (5 ml) and stirred at 90 ° C for 24 hours.
- the reaction solution was filtered, and the obtained resin was washed with chloroform-methanol (1: 1; 5 ml ⁇ 2 times). The filtrate and washings were concentrated.
- a methanol solution of the obtained residue was acidified with 1N hydrochloric acid, and then concentrated to give the title compound (58 mg) having the following physical data.
- the obtained resin (146 mg) was suspended in a 50% trifluoroacetic acid methylene monochloride solution (2 ml) and stirred at room temperature for 30 minutes. The reaction solution was filtered, and washed with methylene chloride (2 ml ⁇ 4 times), methanol (2 ml ⁇ 4 times), and methylene chloride (2 ml ⁇ 4 times). The obtained resin was suspended in a 1.25 M acetic acid-toluene solution (2 ml). The reaction mixture was stirred at 90 for 20 hours. The reaction mixture was filtered and washed with toluene (2 ml ⁇ 3 times) and methanol (2 ml ⁇ 4 times). The filtrate was concentrated to give the title compound (7 mg) having the following physical data.
- Solution A 0.1% trifluoroacetic acid aqueous solution
- Solution B methanol.
- the mixing ratio of solution A and solution B was fixed at 90/10 for 2 minutes after the start of measurement. Thereafter, the mixing ratio of the solution A and the solution B was linearly changed to 2 OZ80 in 20 minutes. Thereafter, the mixing ratio of the aqueous solution and the aqueous solution was fixed at 20 to 80 for 5 minutes. Then, the mixing ratio of solution A and solution B was changed linearly to 90/10 in 1 minute.
- Solution A 0.1% trifluoroacetic acid aqueous solution
- Solution B methanol.
- the mixing ratio of solution A and solution B was fixed at 90/10 for 1 minute after the start of measurement. Then, the mixture ratio of solution A and solution B was changed linearly to 10Z90 for 16 minutes. Thereafter, the mixing ratio of the aqueous solution and the aqueous solution was fixed at 10/90 for 1 minute. Then, the mixing ratio of solution A and solution B was changed linearly to 9 OZ10 in 1 minute.
- Solution A 0.1% trifluoroacetic acid aqueous solution
- Solution B methanol
- the mixing ratio of solution A and solution B was 90/10. Thereafter, the mixing ratio of the solution A and the solution B was linearly changed to 1090 in 16 minutes. Then, the mixture ratio of solution A and solution B was fixed at 10Z90 for 0.5 minutes. Then, the mixture ratio of solution A and solution B was changed linearly to 90/10 in 0.5 minutes.
- Solution A 0.1% trifluoroacetic acid aqueous solution
- Solution B methanol.
- the mixing ratio of solution A and solution B was 90/10. After that, the mixing ratio of solution A and solution B was linearly changed to 1 OZ90 in 5 minutes. Then, the mixing ratio of solution A and solution B was fixed at 1 OZ90 for 0.5 minutes. Then, in 0.1 minute, the mixing ratio of solution A and solution B was changed linearly to 90/10.
- Solution A 0.1% trifluoroacetic acid aqueous solution
- Solution B 0.1% trifluoroacetic acid monoacetonitrile solution.
- the solution is sterilized by a conventional method, filled into ampoules in 5 ml portions, freeze-dried by a conventional method, and an ampoule containing 20 mg of an active ingredient in one ampoule 100 Got a book.
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/531,661 US20060019977A1 (en) | 2002-10-18 | 2002-10-18 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient |
EP02785928A EP1553098A1 (en) | 2002-10-18 | 2002-10-18 | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
PCT/JP2002/010828 WO2004035581A1 (ja) | 2002-10-18 | 2002-10-18 | スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 |
AU2002354054A AU2002354054A1 (en) | 2002-10-18 | 2002-10-18 | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2002/010828 WO2004035581A1 (ja) | 2002-10-18 | 2002-10-18 | スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004035581A1 true WO2004035581A1 (ja) | 2004-04-29 |
Family
ID=32104834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/010828 WO2004035581A1 (ja) | 2002-10-18 | 2002-10-18 | スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060019977A1 (ja) |
EP (1) | EP1553098A1 (ja) |
AU (1) | AU2002354054A1 (ja) |
WO (1) | WO2004035581A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2020246487A1 (ja) * | 2019-06-04 | 2020-12-10 | 第一三共株式会社 | ジスピロジケトピペラジン構造を有する化合物 |
WO2021086038A1 (ko) * | 2019-10-31 | 2021-05-06 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
RU2801811C1 (ru) * | 2019-10-31 | 2023-08-16 | Холосмедик | Новое соединение и содержащая это соединение фармацевтическая композиция для предотвращения или лечения рака |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200413372A (en) * | 2002-09-18 | 2004-08-01 | Ono Pharmaceutical Co | Derivatives of triazaspiro [5.5] undecane and medicants using such derivatives as effective ingredient |
NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
WO2006012173A1 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
MXPA06014572A (es) * | 2004-06-24 | 2007-03-12 | Incyte Corp | Compuestos amido y su uso como farmaceuticos. |
WO2006002350A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
EP1768954A4 (en) * | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS |
CA2570694A1 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
KR20070050076A (ko) * | 2004-08-10 | 2007-05-14 | 인사이트 산 디에고 인코포레이티드 | 아미도 화합물 및 약제로서의 이의 용도 |
CA2585797C (en) * | 2004-11-10 | 2015-01-06 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
US20060122210A1 (en) * | 2004-11-18 | 2006-06-08 | Wenqing Yao | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same |
EP1931652A2 (en) * | 2005-09-21 | 2008-06-18 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
JP5475288B2 (ja) * | 2005-12-05 | 2014-04-16 | インサイト・コーポレイション | ラクタム化合物およびそれを用いる方法 |
WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
BRPI0707408A2 (pt) * | 2006-01-31 | 2011-05-03 | Incyte Corp | compostos de amido e seu uso como produtos farmacêuticos |
TW200808807A (en) * | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
JP2009535420A (ja) * | 2006-05-01 | 2009-10-01 | インサイト・コーポレイション | 11−βヒドロキシルステロイドデヒドロゲナーゼタイプ1のモジュレーターとしてのテトラ置換ウレア |
JP2009537564A (ja) * | 2006-05-17 | 2009-10-29 | インサイト・コーポレイション | 11−βヒドロキシルステロイドデヒドロゲナーゼタイプIの複素環阻害剤およびそれを用いる方法 |
CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
WO2009039431A2 (en) * | 2007-09-21 | 2009-03-26 | Neurogen Corporation | Substituted aryl-fused spirocyclic amines |
WO2016183123A1 (en) * | 2015-05-11 | 2016-11-17 | Alcyone Lifesciences, Inc. | Drug delivery systems and methods |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6504628A (ja) * | 1964-04-10 | 1965-10-11 | ||
JPS4949977A (ja) * | 1972-09-20 | 1974-05-15 | ||
JPS55143980A (en) * | 1979-04-27 | 1980-11-10 | Dai Ichi Seiyaku Co Ltd | Anti-allergic preparation |
JPS5714590A (en) * | 1980-07-02 | 1982-01-25 | Kanto Ishi Pharma Co Ltd | 2-benzyl-5-alkyl-tetrahydro-benzo(b)-1,6-naphthyridin-10-one derivative and its preparation |
JPS5714588A (en) * | 1980-07-02 | 1982-01-25 | Kanto Ishi Pharma Co Ltd | 1- tetrahydro-4-pyridyl -2-substituted-quinazolin-4-one derivative and its preparation |
WO1998025605A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1999037651A1 (en) * | 1998-01-21 | 1999-07-29 | Millenium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO2000042852A1 (en) * | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Compounds and methods |
WO2000066551A1 (fr) * | 1999-04-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Composes d'amides cycliques, leurs procedes de preparation et d'utilisation |
WO2001009138A2 (en) * | 1999-07-28 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2001025200A1 (en) * | 1999-10-01 | 2001-04-12 | Takeda Chemical Industries, Ltd. | Cyclic amine compounds as ccr5 antagonists |
WO2001058867A2 (en) * | 2000-02-14 | 2001-08-16 | Astrazeneca Ab | Novel compounds |
JP2001278886A (ja) * | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
US20010039286A1 (en) * | 2000-02-14 | 2001-11-08 | Kevin Dinnell | 2-aryl indole derivatives and their use as therapeutic agents |
WO2002013824A1 (en) * | 2000-08-17 | 2002-02-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
JP2002348288A (ja) * | 2001-05-28 | 2002-12-04 | Ono Pharmaceut Co Ltd | スピロ複素環誘導体およびそれらを有効成分とする薬剤 |
-
2002
- 2002-10-18 WO PCT/JP2002/010828 patent/WO2004035581A1/ja not_active Application Discontinuation
- 2002-10-18 US US10/531,661 patent/US20060019977A1/en not_active Abandoned
- 2002-10-18 EP EP02785928A patent/EP1553098A1/en not_active Withdrawn
- 2002-10-18 AU AU2002354054A patent/AU2002354054A1/en not_active Abandoned
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6504628A (ja) * | 1964-04-10 | 1965-10-11 | ||
JPS4949977A (ja) * | 1972-09-20 | 1974-05-15 | ||
JPS55143980A (en) * | 1979-04-27 | 1980-11-10 | Dai Ichi Seiyaku Co Ltd | Anti-allergic preparation |
JPS5714590A (en) * | 1980-07-02 | 1982-01-25 | Kanto Ishi Pharma Co Ltd | 2-benzyl-5-alkyl-tetrahydro-benzo(b)-1,6-naphthyridin-10-one derivative and its preparation |
JPS5714588A (en) * | 1980-07-02 | 1982-01-25 | Kanto Ishi Pharma Co Ltd | 1- tetrahydro-4-pyridyl -2-substituted-quinazolin-4-one derivative and its preparation |
WO1998025605A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
US5962462A (en) * | 1996-12-13 | 1999-10-05 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1999037651A1 (en) * | 1998-01-21 | 1999-07-29 | Millenium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2000042852A1 (en) * | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Compounds and methods |
WO2000066551A1 (fr) * | 1999-04-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Composes d'amides cycliques, leurs procedes de preparation et d'utilisation |
WO2001009138A2 (en) * | 1999-07-28 | 2001-02-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
WO2001025200A1 (en) * | 1999-10-01 | 2001-04-12 | Takeda Chemical Industries, Ltd. | Cyclic amine compounds as ccr5 antagonists |
WO2001058867A2 (en) * | 2000-02-14 | 2001-08-16 | Astrazeneca Ab | Novel compounds |
US20010039286A1 (en) * | 2000-02-14 | 2001-11-08 | Kevin Dinnell | 2-aryl indole derivatives and their use as therapeutic agents |
JP2001278886A (ja) * | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
WO2002013824A1 (en) * | 2000-08-17 | 2002-02-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
JP2002348288A (ja) * | 2001-05-28 | 2002-12-04 | Ono Pharmaceut Co Ltd | スピロ複素環誘導体およびそれらを有効成分とする薬剤 |
Non-Patent Citations (9)
Title |
---|
ARMYANSKII KHIMICHESKII ZHURNAL, vol. 25, no. 2, 1972, pages 163 - 167 * |
CHEMICAL ABSTRACTS, vol. 128, no. 13, 1998, Columbus, Ohio, US; abstract no. 154093F, XP002962945 * |
CHEMICAL ABSTRACTS, vol. 132, no. 12, 2000, Columbus, Ohio, US; abstract no. 145995G, XP002962944 * |
CHEMICAL ABSTRACTS, vol. 64, 1966, Columbus, Ohio, US; abstract no. 8204H, 8205A-H, 8206A-F, XP002962946 * |
CHEMICAL ABSTRACTS, vol. 77, 1972, Columbus, Ohio, US; abstract no. 48151S, XP002962947 * |
EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 10, no. 1, 2000, pages 125 - 129 * |
FINKE PAUL E. ET AL.: "Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-(N-(methyl)-N-(phenylsulfonyl)amino)-2-(phenyl)-4-(4-(substituted)piperidin-1-yl)butanes", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, no. 18, 2001, pages 2469 - 2473, XP002962948 * |
MIRZADEGAN TARA ET AL.: "Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 33, 2000, pages 25562 - 25571, XP002941599 * |
YAMATO MASATOSHI ET AL.: "Synthesis and structure-activity relationship of spiro(isochroman-piperidine) analogs for inhibition of histamine release. II", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 29, no. 12, 1981, pages 3494 - 3498, XP000651856 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10874640B2 (en) | 2016-08-26 | 2020-12-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US11420974B2 (en) | 2018-02-26 | 2022-08-23 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2020246487A1 (ja) * | 2019-06-04 | 2020-12-10 | 第一三共株式会社 | ジスピロジケトピペラジン構造を有する化合物 |
WO2021086038A1 (ko) * | 2019-10-31 | 2021-05-06 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
KR20210052322A (ko) * | 2019-10-31 | 2021-05-10 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
JP2023500857A (ja) * | 2019-10-31 | 2023-01-11 | ホロスメディック | 新規な化合物およびそれを含むがんの予防または治療用薬学組成物 |
RU2801811C1 (ru) * | 2019-10-31 | 2023-08-16 | Холосмедик | Новое соединение и содержащая это соединение фармацевтическая композиция для предотвращения или лечения рака |
KR102622152B1 (ko) | 2019-10-31 | 2024-01-08 | 홀로스메딕 주식회사 | 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
JP7471685B2 (ja) | 2019-10-31 | 2024-04-22 | ホロスメディック | 新規な化合物およびそれを含むがんの予防または治療用薬学組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2002354054A1 (en) | 2004-05-04 |
US20060019977A1 (en) | 2006-01-26 |
EP1553098A1 (en) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004035581A1 (ja) | スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤 | |
JP4721087B2 (ja) | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 | |
JP3558079B2 (ja) | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 | |
JPWO2004026873A1 (ja) | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 | |
WO2018089355A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors | |
WO2005023771A1 (ja) | ケモカインレセプターアンタゴニストおよびその医薬用途 | |
JPWO2002074769A1 (ja) | トリアザスピロ[5.5]ウンデカン誘導体を有効成分として含有する薬剤 | |
WO2006022454A1 (ja) | 塩基性基を含有する化合物およびその用途 | |
JP4710606B2 (ja) | スピロピペリジン化合物およびその医薬用途 | |
WO2006006490A1 (ja) | スピロ化合物 | |
WO2007049771A1 (ja) | 塩基性基を含有する化合物およびその用途 | |
AU2017359030A1 (en) | Pyrrole amides as alpha v integrin inhibitors | |
CZ2003284A3 (cs) | 3,4-Dihydroisochinolinový derivát a farmaceutické činidlo obsahující tento derivát jako účinnou složku | |
WO2006129679A1 (ja) | スピロピペリジン化合物およびその医薬用途 | |
JP2002348288A (ja) | スピロ複素環誘導体およびそれらを有効成分とする薬剤 | |
WO2004092136A1 (ja) | 含窒素複素環化合物およびその用途 | |
WO2004094424A1 (ja) | 含窒素複素環化合物およびその用途 | |
JP2004196822A (ja) | トリアザスピロ[5.5]ウンデカン誘導体およびそれらを有効成分とする薬剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006019977 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002785928 Country of ref document: EP Ref document number: 10531661 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002785928 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10531661 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |